Peter Arduini on FDA fasttrack
From GE Healthcare Technologies Inc ($GEHC) Q1 2026 Earnings Call · · Castify Earnings Call
“We recently reached a meaningful clinical milestone with the first patient dosed in our phase 2 and phase three study. This innovation is under FDA fasttrack designation granted to drugs that address serious conditions and unmet needs and can accelerate regulatory review. If successful, both the combination trial and fasttrack designation would speed up the time to market.”
On , Peter Arduini, President, CEO & Director at GE HealthCare Technologies Inc, spoke about FDA fasttrack during GE Healthcare Technologies Inc ($GEHC) Q1 2026 Earnings Call on Castify Earnings Call.
About Peter Arduini
Peter Arduini, president and CEO of GE Healthcare, has been addressing the impact of tariffs and material cost inflation on the company’s financial guidance across recent earnings calls. In the first quarter of 2025, he estimated a $1.75 per share gross tariff impact and announced mitigation actions that